Former Legal & Administration, Corporate Secretary · Alaunos Therapeutics, Inc. (TCRT)

Melinda Lackey

A named executive officer of Alaunos Therapeutics in every fiscal year CompBrief holds from FY2022 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$250,604

Salary $0Stock awards $0

FY2024: $430,370

2nd of 4 named executive officers at Alaunos Therapeutics by FY2025 total.

4 named officers on file for Alaunos Therapeutics, FY2025

Melinda Lackey’s pay file — $29

  • 4 fiscal years of pay, line by line
  • TCRT’s disclosed peer group of 1 company

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Alaunos Therapeutics’s whole pay program stands against its peers

  • Alaunos Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TCRT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2026 (10-K/A).

Free

Get Melinda Lackey’s full pay file as a PDF — free

More than this page: up to 10 years of Melinda’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Melinda Lackey compensation by year

Alaunos Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Alaunos Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023FY2024FY2025
Salary$325,000$312,084$0$0
Bonus$130,000$130,000$0$0
Stock awards$0$0$0$0
Option awards$291,893$76,620$3,087$3,087
Non-equity incentive$0$0$0$0
Pension and deferred compensation$0$0$0$0
All other$17,850$313,033$427,283$249,335
Total$764,743$831,737$430,370$250,604

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Alaunos Therapeutics, Inc. 10-K/A filed April 30, 2026, accession 0001193125-26-197838, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Alaunos Therapeutics, Inc. filed document, accession 0001193125-26-197838. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.

$765K
$832K
$430K
$251K
FY22
FY23
FY24
FY25
SalaryBonusOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option617—$183.00
Option540—$315.00
Option1,406—$2.42
Option750—$75.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Alaunos Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Alaunos Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Holger WeisChief Executive Officer since July 2025$667,766
Melinda Lackey · this pageFormer Legal & Administration, Corporate Secretary$250,604
Ferdinand GroenewaldVice President, Finance$216,988
Dale HogueFormer Interim Chief Executive Officer as of July 2025$143,492

The full Alaunos Therapeutics compensation record

free company brief

This page is one person within Alaunos Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Alaunos Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Alaunos Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Melinda Lackey's compensation dossier · One-time report. No refunds.